Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 1.33
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's,...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Data is available to registered users only
Target Price
Buy
Sell